ESC Cardio-Oncology 2026 (ESCardioOnco26), held on 19–20 June 2026 at the Austria Center Vienna in Vienna, Austria, brought together specialists across cardiology, oncology, haematology, radiotherapy, and allied disciplines. Organised by the ESC Council of Cardio-Oncology, the second edition of the meeting focused on advancing interdisciplinary care, translating emerging research into clinical practice, and improving cardiovascular outcomes for people living with and beyond cancer.
15 Posts Not To Miss From ESCardioOnco26
“Speaking about ‘Defining Cardiovascular Endpoints in Oncology Trials’ at ES Cardio-Oncology 2026, only a few days after the publication of the manuscript led by Dr. Ana Barac.”
“Great days at ESCardioOnco26.
I am happy and inspired by the discussions, and excited about the new collaborations ahead.
Proud of my enthusiastic group members for their work and excellent presentations.”
“Time for debate: Is echocardiographic surveillance mandatory in metastatic HER2-positive breast cancer?
The key takeaway is that longer survival calls for smarter, risk-based follow-up. Surveillance should be tailored to each patient’s risk of cancer therapy–related cardiac dysfunction.
Monitoring is also important with trastuzumab deruxtecan, and as anti-HER2 therapies are increasingly used across other solid tumors, including gastrointestinal cancers.”
“That’s a wrap for ESCardioOnco26.
A spectacular, inspiring, and energizing meeting. Thank you to Teresa López-Fernández and the entire ES Cardio-Oncology community.”
“Are you ready to start?
At ESCardioOnco26, join us for a dynamic session exploring drug–drug interactions, cardiovascular adverse-event reporting, QT prolongation, and the future of cardio-oncology pharmacology.
The session will be packed with practical insights and expert discussion.”
“It was an honor to present ‘The Cardiologist Perspective’ during The Resilience Project sessions at ES Cardio-Oncology 2026.
Working together with oncologists and hematologists is the means; improving cardiovascular safety for patients with cancer is the goal.”
“As ESCardioOnco26 comes to a close, local hosts Prof. Irene Lang and Prof. Franz Weidinger reflected on an inspiring meeting filled with outstanding science, engaging discussions, and international collaboration.
From thrombosis, atrial fibrillation, imaging, and cardiotoxicity to highly engaging clinical cases, posters, and COOL sessions, the congress highlighted the continued growth and rapid evolution of cardio-oncology.
Throughout the meeting, multidisciplinary collaboration was on full display, bringing together cardiologists, oncologists, hematologists, radiation oncologists, scientists, nurses, and allied healthcare professionals to exchange knowledge and advance patient care.”
“Development and validation of a novel nomogram for predicting bleeding risk in patients with concomitant cancer and atrial fibrillation.”
International Cardio-Oncology Society:
“Excited to be supporting our friends at ESCardioOnco26 and the European Society of Cardiology.
If you are attending and passionate about international cardio-oncology collaboration, let’s connect.”
“ESCardioOnco26 kicks off today in Vienna.
Two days of outstanding science, inspiring discussions, and collaboration across cardiology, oncology, and hematology—all focused on improving outcomes for patients with cancer.”
“Excellent session on the future of cardio-oncology.
It was particularly encouraging to see Portugal represented by Julia Toste alongside international leaders in the field.
As cardio-oncology continues to grow, investment in education, training, and global collaboration remains essential.”
“Pedro Moliner addresses key questions around atrial fibrillation in patients with cancer at ESCardioOnco26.”
Written by Nare Hovhannisyan, MD
Stay informed with more articles like this on OncoDaily